Skip to Content

'
Samuel C. Mok

Present Title & Affiliation

Primary Appointment

Professor, Department of Gynecologic Oncology - Research, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Dual/Joint/Adjunct Appointment

Professor, Biology, Division of Basic Science Research, The Chinese University of Hong Kong, Hong Kong, Hong Kong

Bio Statement

 My laboratory has a primary research focus on the use of molecular biological techniques to investigate the pathogenesis of invasive ovarian cancer and borderline epithelial ovarian tumors. The laboratory has pursued studies of genetic changes in tissues from invasive ovarian cancer and borderline tumors to better understand the potential relationship between these two entities and to termine basic mechanisms of development. Studies from the laboratory indicate that the pathway of pathogenesis of borderline ovarian tumors is distinct from that of invasive ovarian cancers. Furthermore, we also showed that advanced ovarian cancer is unifocal in origin, thereby indicating the opportunity for early diagnosis. My laboratory’s ongoing research projects involve the use of oligonucleotide microarrays and SNP arrays to identify differentially expressed genes and DNA copy number abnormalities in microdissected primary and recurrent ovarian tumor tissue samples of different histological types, stages, and grades, correlation between expression profile data and clinical outcomes including chemoresponse and survival, and functional studies of genes that may be of clinicopathological significance. These studies will generate biomarkers for the development of a pathway model for the genetic progression of ovarian cancer, provide insights into their roles in ovarian carcinogenesis, provide markers for early diagnosis of ovarian cancer, and new therapeutic targets for treatment.

Besides using oligonucleotide microarrays to identify markers for ovarian cancer, my Laboratory is also focusing on using oligonucleotide microarrays, SELDI ProteinChips, MALDI-TOF/TOF mass spectrometry, and 2D differential gel electrophoresis to identify markers, including RNA, peptides, and autoantibodies, in serum, or plasma samples obtained from ovarian cancer patients. We are developing a new nanochip platform, which can be used to quantify serum/plasma biomarkers.  

My Laboratory is also interested in understanding how various endogenous factors such as reproductive and genetic factors, and environmental factors interact to modify ovarian cancer risk. Ongoing research projects involve studies on the effect of various endogenous factors, such as genetic polymorphism, and environmental factors on ovarian cancer risk. In addition, we have recently developed a three-dimensional normal HOSE spheroid Matrigel model, which will be used to study epithelial and stromal cell interaction in ovarian cancer pathogenesis.

In addition, we are interested in the application of targeted nanoparticles to increase efficacy and decrease toxicity in ovarian cancer treatment.

Research Interests

  1. Identification of differentially expressed genes in human epithelial ovarian cancer
  2. Genetic alterations in human borderline ovarian tumor
  3. Genetic alterations in papillary seous carcinoma of the peritoneum
  4. Role of signal transduction molecules in ovarian carcinogenesis
  5. Molecular classification of epithelial ovarian tumors
  6. Identification of markers for early detection of ovarian cancer
  7. Stromal and epithelial cell interaction in ovarian cancer pathogenesis
  8. Genetic polymorphisms and ovarian cancer risk
  9. Application of nantotechnology in ovarian cancer detection and treatment

Education & Training

Degree-Granting Education

1987 The Chinese University of Hong Kong, Hong Kong, Hong Kong, PHD, Anatomy
1984 The Chinese University of Hong Kong, Hong Kong, Hong Kong, BS, Biology

Postgraduate Training

1990-1992 Research Fellowship, Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
1989-1990 Research Fellowship, Department of Immunology, Toronto Western Hospital, Toronto, Canada
1987-1989 Postdoctoral Fellow, Dept of Clinical Biochemistry, University of Toronto, Toronto, Ontario, Canada

Selected Publications

Peer-Reviewed Original Research Articles
1. Mok SC, Bonome T, Bell A, Johnson ME, Park DE, Hao K, Yip DKP, Donninger H, Brady J, Randoovich M, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ. A gene signature predictive for outcome in advanced ovarian cancer identifies a novel survival factor: microfibril-associated glycoprotein 2. Cancer Cell. In Press.
2. Alper O, Stetler-Stevenson WG, Harris LN, Leitner WW, Ozdemirli M, Hartmann D, Raffeld M, Abu-Asab M, Byers S, Zhuang Z, Oldfield EH, Tong Y, Bergmann-Leitner E, Criss WE, Nagasaki K, Mok SC, Cramer DW, Karaveli FS, Goldbach-Mansky R, Leo P, Stromberg K, Weil RJ. Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci. e-Pub 6/17/2009. PMID: 19594548.
3. Tung CS, Mok SC, Tsang TYM. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. e-Pub 6/12/2009. PMID: 19525924.
4. Chung TK, Cheung TH, Huen NY, Wong KW, Lo KW, Yim SF, Siu NS, Wong YM, Tsang PT, Pang MW, Yu MY, To KF, Mok SC, Wang VW, Li C, Cheung AY, Doran G, Birrer MJ, Smith DI, Wong YF. Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124(6):1358-65, 3/2009. PMID: 19065659.
5. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia 11(2):126-35, 2/2009. PMCID: PMC2631137.
6. Nevadunsky NS, Barbieri JS, Kwong J, Merritt MA, Welch WR, Berkowitz RS, Mok SC. RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol 112(2):325-30, 2/2009. e-Pub 10/2008. PMID: 18937968.
7. Callahan MJ, Nagymanyoki Z, Bonome T, Johnson ME, Litkouhi B, Sullivan EH, Hirsch MS, Matulonis UA, Liu J, Birrer MJ, Berkowitz RS, Mok SC. Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res 14(23):7667-73, 12/1/2008. PMID: 19047092.
8. Park DC, Yeo SG, Wilson MR, Yerbury JJ, Kwong J, Welch WR, Choi YK, Birrer MJ, Mok SC, Wong KK. Clusterin interacts with Paclitaxel and confer Paclitaxel resistance in ovarian cancer. Neoplasia 10(9):964-72, 9/2008. PMCID: PMC2517641.
9. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in intraplacental and postmolar choriocarcinomas. J Reprod Med 53(8):558-64, 8/2008. PMID: 18773618.
10. Aponte M, Jiang W, Lakkis M, Li MJ, Edwards D, Albitar L, Vitonis A, Mok SC, Cramer DW, Ye B. Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer. Cancer Res 68(14):5839-48, 7/15/2008. PMID: 18632638.
11. Nagymanyoki Z, Butler MO, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Antigen-specific T cell immune response detected by skewed T cell receptor usage in normal placenta and complete molar pregnancy. J Reprod Med 53(7):528-34, 7/2008. PMID: 18720929.
12. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y. S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther 7(7):1993-2002, 7/2008. PMID: 18645009.
13. Litkouhi B, Litkouhi B, Fleming E, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms. Gynecol Oncol 109(2). e-Pub 3/10/2008. PMID: 18331757.
14. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 14(3):764-71, 2/1/2008. PMID: 18245537.
15. Stany MP, Bonome T, Wamunyokoli F, Zorn K, Ozbun L, Park DC, Hao K, Boyd J, Sood AK, Gershenson DM, Berkowitz RS, Mok SC, Birrer MJ. Classification of ovarian cancer: a genomic analysis. Adv Exp Med Biol 622:23-33, 2008. PMID: 18546616.
16. Merritt WM, Lin YG, Han LY, Kamat AA, Spannuth WA, et al. Dicer, drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359:2642-2650, 2008.
17. Koon EC, Ma PC, Salgia R, Welch WR, Christensen JG, Berkowitz RS, Mok SC. Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int J Gynecol Cancer 18(5). e-Pub 11/16/2007. PMID: 18021219.
18. Nagymanyoki Z, Callahan MJ, Parast MM, Berkowitz RS, Mok SC, Fulop V. Overexpression of laminin receptor 1 on decidual cells in partial and complete mole. Gynecol Oncol 108(1). e-Pub 10/24/2007. PMID: 17928039.
19. Nagymanyoki Z, Callahan MJ, Parast MM, Fulop V, Mok SC, Berkowitz RS. Immune cell profiling in normal pregnancy, partial and complete molar pregnancy. Gynecol Oncol 107(2). e-Pub 9/18/2007. PMID: 17878059.
20. Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC. Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106(2):311-7, 8/2007. e-Pub 5/25/2007. PMCID: PMC1995602.
21. Birrer MJ, Johnson ME, Hao K, Wong KK, Park DC, Bell A, Welch WR, Berkowitz RS, Mok SC. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol 25(16):2281-7, 6/1/2007. PMID: 17538174.
22. Litkouhi B, Kwong J, Lo CM, Smedley JG, McClane BA, Aponte M, Gao Z, Sarno JL, Hinners J, Welch WR, Berkowitz RS, Mok SC, Garner EI. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9(4):304-14, 4/2007. PMCID: PMC1854850.
23. Nishimura S, Tsuda H, Ito K, Jobo T, Yaegashi N, Inoue T, Sudo T, Berkowitz RS, Mok SC. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol 38(1):134-9, 1/2007. e-Pub 9/25/2006. PMID: 16996567.
24. Said NA, Najwer I, Socha MJ, Fulton DJ, Mok SC, Motamed K. SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 9(1):23-35, 1/2007. PMCID: PMC1803033.
25. Park DC, Yeo SG, Shin EY, Mok SC, Kim DH. Clusterin confers paclitaxel resistance in cervical cancer. Gynecol Oncol 103(3):996-1000, 12/2006. e-Pub 8/4/2006. PMID: 16890274.
26. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, Mok SC, Brady J, Bonome T, Birrer MJ. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 66(17):8404-12, 9/1/2006. PMID: 16951150.
27. Kim KS, Sengupta S, Berk M, Kwak YG, Escobar PF, Belinson J, Mok SC, Xu Y. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66(16):7983-90, 8/15/2006. PMID: 16912173.
28. Huang KC, Park DC, Ng SK, Lee JY, Ni X, Ng WC, Bandera CA, Welch WR, Berkowitz RS, Mok SC, Ng SW. Selenium binding protein 1 in ovarian cancer. Int J Cancer 118(10):2433-40, 5/15/2006. PMID: 16380993.
29. Kwong J, Lee JY, Wong KK, Zhou X, Wong DT, Lo KW, Welch WR, Berkowitz RS, Mok SC. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8(4):268-78, 4/2006. PMCID: PMC1600675.
30. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC. PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol 101(1):71-5, 4/2006. e-Pub 11/10/2005. PMID: 16290000.
31. Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, Cramer DW. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 12(2):432-41, 1/15/2006. PMID: 16428483.
32. Feinberg BB, Jack RM, Mok SC, Anderson DJ. Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations. Am J Reprod Immunol 54(6):352-7, 12/2005. PMID: 16305660.
33. Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602-12, 11/15/2005. PMID: 16288054.
34. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res 11(21):7651-7, 11/1/2005. PMID: 16278384.
35. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99(2):267-77, 11/2005. e-Pub 8/2/2005. PMID: 16061277.
36. Tsuda H, Ito YM, Ohashi Y, Wong KK, Hashiguchi Y, Welch WR, Berkowitz RS, Birrer MJ, Mok SC. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11(19 Pt 1):6880-8, 10/1/2005. PMID: 16203778.
37. Wang V, Li C, Lin M, Welch W, Bell D, Wong YF, Berkowitz R, Mok SC, Bandera CA. Ovarian cancer is a heterogeneous disease. Cancer Genet Cytogenet 161(2):170-3, 9/2005. PMID: 16102589.
38. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 5(12):3183-92, 8/2005. PMID: 16035113.
39. Zhou X, Rao NP, Cole SW, Mok SC, Chen Z, Wong DT. Progress in concurrent analysis of loss of heterozygosity and comparative genomic hybridization utilizing high density single nucleotide polymorphism arrays. Cancer Genet Cytogenet 159(1):53-7, 5/2005. PMID: 15860358.
40. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, Hecht JL. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 65(6):2162-9, 3/15/2005. PMID: 15781627.
41. Huddleston HG, Wong KK, Welch WR, Berkowitz RS, Mok SC. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker. Gynecol Oncol 96(1):77-83, 1/2005. PMID: 15589584.
42. Feltmate CM, Mok SC. Whole-genome allelotyping using laser microdissected tissue. Methods Mol Biol 293:69-77, 2005. PMID: 16028411.
43. Tsuda H, Birrer MJ, Ito YM, Ohashi Y, Lin M, Lee C, Wong WH, Rao PH, Lau CC, Berkowitz RS, Wong KK, Mok SC. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform. Cancer Genet Cytogenet 155(2):97-107, 12/2004. PMID: 15571795.
44. Zhou X, Mok SC, Chen Z, Li Y, Wong DT. Concurrent analysis of loss of heterozygosity (LOH) and copy number abnormality (CNA) for oral premalignancy progression using the Affymetrix 10K SNP mapping array. Hum Genet 115(4):327-30, 9/2004. PMID: 15290239.
45. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211(2):227-34, 8/10/2004. PMID: 15219946.
46. Ni X, Zhang W, Huang KC, Wang Y, Ng SK, Mok SC, Berkowitz RS, Ng SW. Characterization of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 91(4):725-31, 8/2004. PMID: 15305183.
47. Schorge JO, Drake RD, Lee H, Skates SJ, Rajanbabu R, Miller DS, Kim JH, Cramer DW, Berkowitz RS, Mok SC. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. Clin Cancer Res 10(10):3474-8, 5/15/2004. PMID: 15161704.
48. Zhou X, Li C, Mok SC, Chen Z, Wong DT. Whole genome loss of heterozygosity profiling on oral squamous cell carcinoma by high-density single nucleotide polymorphic allele (SNP) array. Cancer Genet Cytogenet 151(1):82-4, 5/2004. PMID: 15120915.
49. Tsuda H, Bandera CA, Birrer MJ, Hashiguchi Y, Berkowitz RS, Mok SC. Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary. Oncology 67(3-4):291-9, 2004. PMID: 15557791.
50. Batorfi J, YE B, Mok SC, Cseh I, Berkowitz RS, Fulop V. Protein profiling of complete mole and normal placenta using ProteinChip analysis on laser capture microdissected cells. Gynecol Oncol 88:424-428, 2003.

Invited Articles
1. Mok SC, Wong KK, Lu K, Nagymanyoki Z. Molecular basis of gynecologic diseases. Molecular Pathology. In Press.
2. Wong KK, Mok SC. Molecular genetics of ovarian cancer. Ovarian Cancer. In Press.
3. Lu KH, Yates MS, Mok SC. The monkey, the hen, and the mouse: Models to advance ovarian cancer chemoprevention. Cancer Epidemiology, Biomarkers & Prevention. In Press.
4. Tung C, Wong KK, Mok SC. Biomarker discovery in ovarian cancer. Womens Health (Lond Engl) 4:27-40, 2008. PMID: 19072449.
5. Ye B, Gagnon A, Mok SC. Recent technical strategies to identify diagnostic biomarkers for ovarian cancer. Expert Rev Proteomics 4(1):121-31, 2/2007. PMID: 17288520.
6. Mok SC, Elias KM, Wong KK, Ho K, Bonome T, Birrer MJ. Biomarker discovery in epithelial ovarian cancer by genomic approaches. Adv Cancer Res 96:1-22, 2007. PMID: 17161674.
7. Samimi G, Ozbun L, Johnson ME, Mok SC, Birrer MJ. Biomarkers of mucinous tumors of the ovary. Dis Markers 23(5-6):389-96, 2007. PMID: 18057522.
8. Mok SC, Kwong J, Welch WR, Samimi G, Ozbun L, Bonome T, Birrer MJ, Berkowitz RS, Wong KK. Etiology and pathogenesis of epithelial ovarian cancer. Dis Markers 23(5-6):367-76, 2007. PMID: 18057520.
9. Mok SC, Kwong J, Welch WR, et al. Etiology and pathogenesis of epithelial ovarian cancer. Disease Biomarkers 23:367-376, 2007.
10. Fulop V, Mok SC, Berkowitz RS. Molecular biology of gestational trophoblastic neoplasia: a review. J Reprod Med 49(6):415-22, 6/2004. PMID: 15283047.
11. Terry KL, Sluss PM, Skates SJ, Mok SC, Ye B, Vitonis AF, Cramer DW. Blood and urine markers for ovarian cancer: a comprehensive review. Dis Markers 20(2):53-70, 2004. PMID: 15322314.
12. Bandera CA, Ye B, Mok SC. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 15(1):51-5, 2/2003. PMID: 12544502.
13. Fulop V, Mod SC, Gati I, Berkowitz RS. Recent advances in molecular biology of gestational trophoblastic diseases. J Reprod Med 47:369-379, 2002.

Book Chapters
1. Mok SC, Wong KK, Lu KH, Munger K. Molecular Basis of Gynecologic Diseases. In: Molecular Basis of Human Diseases. Elsevier Science Press. In Press.
2. Wong KK, Mok SC. Molecular genetics of ovarian cancer. In: In Ovarian Cancer, 2009.
3. Feltmate C, Mok SC. Whole genome allelotyping on laser-based microdissected tissue. In: Laser Capture Microdissection: methods and protocols. Ed(s) I Graeme, M Curran and Stephanie Curran. The Humana Press Inc: Totowa, New Jersey, 69-77, 2004.
4. Wong KK, Cheng R, Kim JK, Mok SC. Gene expression analysis of ovarian tumors with a cDNA microarray containing ovarian tumor-specific clones. In: Perspectives In Gene Expression. Ed(s) K Appasani. BioTechniques Press: Natick, Massachusettes, 2003.
5. Mok SC, Schorge JO, Welch WR, Hendrickson MR, Kempson RL. Peritoneal Tumours. In: World Health Organization of Tumours, Pathology & Genetics, Tumours of the Breast and Female Genital Organs. Ed(s) FA Tavassoli, P Devilee. IARC Press, 197-202, 2003.
6. Wong KK, Cheng RS, Berkowitz RS, Mok SC. Gene expression analysis of ovarian cancer cells by cDNA microarray. In: Microarray and Cancer. Ed(s) J Warrington, CR Todd, D Wong. Eaton Publishing: Natick, Massachusetts, 127-138, 2002.
7. Mok SC, Lu KH, Ng SW, Yiu GK, Welch WR, Bell DA, Berkowitz RS. Molecular pathogenesis of borderline and invasive ovarian tumors. In: Ovarian Cancer 6. Ed(s) I Jacobs, D Luesley, A Berchuck, T Blackett. Isis Medical Media, 97-103, 2000.

Grant & Contract Support

Title: Epithelial stromal interaction in ovarian cancer progression
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 10/1/2009 - 9/30/2011
 
Title: CNV and ovarian cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Charles Lee
Duration: 7/1/2009 - 6/30/2014
 
Title: Prognostic markers for ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 3/1/2009 - 12/31/2014
 
Title: A fresh approach to identification and characterization of early changes of disease associated with ovarian cancer
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Gordon Mills
Duration: 2009 - present
 
Title: Early events in ovarian cancer pathogenesis
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Anil Sood
Duration: 2009 - present
 
Title: Application of nanotechnology in the targeted release of anticancer drugs in ovarian cancer treatment
Funding Source: Department of Defense (DOD)
Role: Co-Investigator
Principal Investigator: Coleen Feltmate
Duration: 2006 - 2008
 
Title: Urine protein biomarker exploration in ovarian cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Bin Ye
Duration: 9/9/2005 - 9/9/2007
 
Title: DF/HCC Ovarian Cancer, Early genetic changes in ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2004 - 2008
 
Title: Prognostic markers for ovarian cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2003 - 7/30/2009
 
Title: Genes, Hormones and Environment in ovarian cancer model
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Daniel Cramer
Duration: 2003 - 2008
 
Funding Source: Friends of Dana-Farber
Role: Principal Investigator
Duration: 2003 - 2004
 
Title: Maternal obesity, intrauterine gene expession and breast cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Karin Michels
Duration: 2002 - 2005
 
Title: Identification of markers for early detection of ovarian cancer
Funding Source: Adler Foundation, Inc
Role: Principal Investigator
Duration: 2001 - 2005

Last updated: 9/11/2009